Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.
Koutnikova H, Laakso M, Lu L, Combe R, Paananen J, Kuulasmaa T, Kuusisto J, Häring HU, Hansen T, Pedersen O, Smith U, Hanefeld M, Williams RW, Auwerx J. Koutnikova H, et al. Among authors: hanefeld m. PLoS Genet. 2009 Aug;5(8):e1000591. doi: 10.1371/journal.pgen.1000591. Epub 2009 Aug 7. PLoS Genet. 2009. PMID: 19662162 Free PMC article.
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. Chiasson JL, et al. Among authors: hanefeld m. Diabetes Care. 1998 Oct;21(10):1720-5. doi: 10.2337/diacare.21.10.1720. Diabetes Care. 1998. PMID: 9773737 Clinical Trial.
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Chiasson JL, et al. Among authors: hanefeld m. Diabetologia. 2004 Jun;47(6):969-75; discussion 976-7. doi: 10.1007/s00125-004-1409-4. Epub 2004 May 26. Diabetologia. 2004. PMID: 15164169 Clinical Trial.
Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; RECORD Study Group. Home PD, et al. Among authors: hanefeld m. Diabet Med. 2007 Jun;24(6):626-34. doi: 10.1111/j.1464-5491.2007.02160.x. Diabet Med. 2007. PMID: 17517066 Free PMC article. Clinical Trial.
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, et al. Among authors: hanefeld m. Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8. Lancet. 2006. PMID: 16997664 Free article. Clinical Trial.
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Zoungas S, et al. N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19. N Engl J Med. 2014. PMID: 25234206 Free article. Clinical Trial.
399 results